Leaderboards/EGFR

EGFR

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Vlado Perkovic
University of Copenhagen
1.4k cit.
2
Julien Dilly
Broad Institute
672 cit.
3
Rongxuan Zhu
Zhejiang Cancer Hospital
606 cit.
4
Helen M. Colhoun
Edinburgh Cancer Research
561 cit.
5
James Chih‐Hsin Yang
National Taiwan University Hospital
472 cit.
6
Luís Nunes
Uppsala University
393 cit.
7
D. Ross Camidge
University of Colorado Cancer Center
372 cit.
8
Byoung Chul Cho
Harbin Medical University
360 cit.
9
Jinzhuo Wang
Center for Life Sciences
336 cit.
10
Natasha B. Leighl
Princess Margaret Cancer Centre
321 cit.

Rising Stars Papers

1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
New England Journal of Medicine|2024
1.4k cit.
2
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
PubMed|2025
933 cit.
3
BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
PubMed|2025
844 cit.
4
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Cancer Discovery|2024
223 cit.
5
ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion
Cell Metabolism|2024
201 cit.
6
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Nature Medicine|2024
186 cit.
7
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant
JAMA|2024
156 cit.
8
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
Journal of Clinical Oncology|2024
133 cit.
9
Prognostic genome and transcriptome signatures in colorectal cancers
Nature|2024
130 cit.
10
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Journal of Clinical Oncology|2024
123 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Donald M. O’Rourke
Translational Therapeutics (United States)
476 cit.
2
Sheng Yao
BioReliance (United States)
474 cit.
3
James Chih‐Hsin Yang
National Taiwan University Hospital
340 cit.
4
Jonathan Barratt
University of Leicester
324 cit.
5
Wendy R. Parulekar
Ontario Institute for Cancer Research
274 cit.
6
Byoung Chul Cho
Yonsei University
255 cit.
7
Pasi A. Jänne
Dana-Farber Cancer Institute
216 cit.
8
Martin Reck
The University of Texas MD Anderson Cancer Center
215 cit.
9
Kunihiko Kobayashi
Harbin Medical University
206 cit.
10
Yi‐Long Wu
Chinese Academy of Medical Sciences & Peking Union Medical College
198 cit.

Emerging Leaders Papers

1
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Nature Medicine|2024
317 cit.
2
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
JAMA|2024
316 cit.
3
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology|2023
274 cit.
4
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
The Lancet|2023
270 cit.
5
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Annals of Oncology|2023
382 cit.
6
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
The Lancet|2023
251 cit.
7
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
Journal of Clinical Oncology|2024
146 cit.
8
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal of Clinical Oncology|2023
216 cit.
9
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
New England Journal of Medicine|2023
644 cit.
10
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine|2023
617 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Matthew Meyerson
Broad Institute
28.2k cit.
2
D. Neil Hayes
University of North Carolina at Chapel Hill
23.1k cit.
3
Harold Varmus
Memorial Sloan Kettering Cancer Center
16.5k cit.
4
Pasi A. Jänne
Massachusetts General Hospital
13.4k cit.
5
Masahiro Fukuoka
Kindai University
12.3k cit.
6
Wendy R. Parulekar
Ontario Institute for Cancer Research
11.6k cit.
7
Daniel A. Haber
Harvard University
11.5k cit.
8
Mostafa A. El‐Sayed
Georgia Institute of Technology
10.8k cit.
9
Solange Peters
University Hospital of Lausanne
9.8k cit.
10
Martin Schüler
Unknown
9.6k cit.

All-Time Leaders Papers

1
Comprehensive molecular portraits of human breast tumours
Nature|2012
12.3k cit.
2
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science|2004
9.4k cit.
3
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Cancer Cell|2010
7.7k cit.
4
Comprehensive molecular profiling of lung adenocarcinoma
Nature|2014
5.8k cit.
5
The Somatic Genomic Landscape of Glioblastoma
Cell|2013
5.1k cit.
6
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science|2007
4.5k cit.
7
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences|2004
4.3k cit.
8
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Nature|2015
4.1k cit.
9
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology|2007
3.9k cit.
10
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine|2004
11.5k cit.

All-Time Leaders Reagents

Coming soon

Indexing EGFR Reagents

Citation data for reagents in this field is currently compiling.